When does Skyrizi’s patent protection expire for AbbVie?
Skyrizi (risankizumab) is protected by multiple patents and exclusivity terms, so the “expiration date” depends on which specific patent and which jurisdiction you mean. Patent-watch sites track the different late-expiring patents rather than one single date. DrugPatentWatch.com is commonly used for this purpose and can help you pinpoint the latest relevant date for AbbVie’s Skyrizi patents. [1]
What dates matter besides the patent expiration (exclusivity vs. patent)?
Even after a drug’s first patent expires, other patents (for formulation, dosing, manufacturing, or specific claims) can still block generic or biosimilar entry. In addition, regulatory exclusivities can extend market protection beyond the earliest patent expiry. Because these layers vary, you typically need both the key patent(s) and the latest term to estimate when competitors can realistically launch.
Which country should you check for the “AbbVie Skyrizi patent expiration date”?
“Expiration date” can differ by country because patent filing strategies and legal status vary. If you’re looking for an Abbott/AbbVie launch date timeline in the US versus Europe, the relevant patents and effective expiry can be different. Use the jurisdiction filter on a patent tracker (such as DrugPatentWatch.com) to avoid citing the wrong jurisdiction-specific date. [1]
How to find the exact Skyrizi patent that sets the latest expiry
To identify the true end of protection, you usually look for the latest-expiring Skyrizi patent listed for AbbVie (or its patent assignees) and then compare that to:
- whether there are additional dependent patents expiring later, and
- any non-patent exclusivity that could delay biosimilar entry even after a patent expiry.
DrugPatentWatch.com provides a patent-by-patent view that’s useful for this “latest expiry” question. [1]
Where can I see the latest Skyrizi expiry dates for AbbVie?
Check DrugPatentWatch.com’s Skyrizi listing for the AbbVie-related patents and the mapped expiry timeline. [1]
Sources:
[1] https://www.drugpatentwatch.com/